Literature DB >> 19248843

Immunomodulatory role of prolactin in diabetes development.

P Cejkova1, M Fojtikova, M Cerna.   

Abstract

Pituitary hormone and cytokine prolactin (PRL) is one of the mediators of the bidirectional communication between neuroendocrine and immune systems. It participates in many immunomodulatory activities, affects differentiation and maturation of both, B and T lymphocytes and enhances inflammatory responses and production of immunoglobulins. Hyperprolactinemia has been described in many autoimmune diseases, both systemic (SLE, RA, PsA) and organ-specific (T1D, CD and others) and the activity of PRL has been intensively studied. Nevertheless, no data on PRL contribution to pathogenesis of diabetes mellitus is available, although the effect of PRL on beta cells of the pancreas and insulin secretion has been observed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248843     DOI: 10.1016/j.autrev.2009.02.031

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

1.  Reproductive immunology: a focus on the role of female sex hormones and other gender-related factors.

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

2.  Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Mona Boaz; Nancy Agmon-Levin; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Andrea Doria; Anna Ghirardello; Jesus Gomez-Arbesu; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz' Rozman; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

3.  Properties of antibodies to a synthetic peptide representing an epitope shared by receptors of the type I cytokine family.

Authors:  Carlos G Belloc; Marisol Aguirre; Clara Peña; José L Aparicio; Maite Duhalde Vega; Sarah Dormois; Lilia A Retegui
Journal:  Clin Exp Med       Date:  2013-02       Impact factor: 3.984

4.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

Review 5.  Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models.

Authors:  Subhrajit Saha; Arlene Tieng; K Peter Pepeljugoski; Gisele Zandamn-Goddard; Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

6.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

7.  Circulating prolactin concentrations and risk of type 2 diabetes in US women.

Authors:  Jun Li; Megan S Rice; Tianyi Huang; Susan E Hankinson; Charles V Clevenger; Frank B Hu; Shelley S Tworoger
Journal:  Diabetologia       Date:  2018-10-11       Impact factor: 10.122

8.  Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

Authors:  Lisa Balbach; Henri Wallaschofski; Henry Völzke; Matthias Nauck; Marcus Dörr; Robin Haring
Journal:  BMC Endocr Disord       Date:  2013-03-21       Impact factor: 2.763

9.  Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study.

Authors:  Tiange Wang; Jieli Lu; Yu Xu; Mian Li; Jichao Sun; Jie Zhang; Baihui Xu; Min Xu; Yuhong Chen; Yufang Bi; Weiqing Wang; Guang Ning
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

10.  PRLR regulates hepatic insulin sensitivity in mice via STAT5.

Authors:  Junjie Yu; Fei Xiao; Qian Zhang; Bin Liu; Yajie Guo; Ziquan Lv; Tingting Xia; Shanghai Chen; Kai Li; Ying Du; Feifan Guo
Journal:  Diabetes       Date:  2013-06-17       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.